Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Harvard Business School
Merck
Boehringer Ingelheim
Medtronic

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Patent: 10,383,876

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,383,876
Title:Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Abstract: The present invention relates:--to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-- c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof;--to methods of preparing said dihydrochloride salt;--to said dihydrochloride salt for the treatment and/or prophylaxis of a disease;--to the use of said dihydrochloride salt for the preparation of a medicament for the treatment and/or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, more particularly for the treatment or prophylaxis of a cancer, particularly lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, hepatocyte carcinoma, pancreatic cancer, hepatocyte carcinoma or breast cancer;--to a pharmaceutical composition comprising said dihydrochloride salt; and--to a pharmaceutical combination comprising said dihydrochloride salt in combination with one or more further pharmaceutical agents. ##STR00001##
Inventor(s): Peters; Jan-Georg (Solingen, DE), Militzer; Hans-Christian (Odenthal, DE), Muller; Hartwig (Velbert, DE)
Assignee: BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE)
Application Number:14/009,599
Patent Claims:see list of patent claims

Details for Patent 10,383,876

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 1978-01-10 ⤷  Free Forever Trial 2031-04-05
Amgen, Inc. EPOGEN/PROCRIT epoetin alfa Injection 103234 1989-06-01 ⤷  Free Forever Trial 2031-04-05
Amgen, Inc. EPOGEN/PROCRIT epoetin alfa Injection 103234 ⤷  Free Forever Trial 2031-04-05
Amgen, Inc. PROCRIT epoetin alfa Injection 103234 ⤷  Free Forever Trial 2031-04-05
Clinigen, Inc. PROLEUKIN aldesleukin For Injection 103293 1992-05-05 ⤷  Free Forever Trial 2031-04-05
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 1991-02-20 ⤷  Free Forever Trial 2031-04-05
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 2000-06-28 ⤷  Free Forever Trial 2031-04-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
McKesson
Johnson and Johnson
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.